Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Campbell

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
JAMA Pediatrics|March 20, 2018
Considerations for Cost-effectiveness Analysis of Curative Pediatric TherapiesMelanie D Whittington, R Brett McQueen, Jonathan D Campbell
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 6, 2008
Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthmaJonathan D Campbell, David K Blough, Sean D Sullivan
Health Affairs Scholar|September 8, 2025
Inflation reduction act impact on pharmaceutical investment: insights from investor interviewsWilliam J Canestaro, Julie A Patterson, Jonathan D Campbell
Neurology. Clinical Practice|May 1, 2018
Achieving high value care for all and the perverse incentives of 340B price agreementsMelanie D Whittington, Jonathan D Campbell, R Brett McQueen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment ImplicationsMelanie D Whittington, R Brett McQueen, Jonathan D Campbell
Hospital Pharmacy|May 6, 2022
Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant InfectionsMonica L Bianchini, Meghan N Jeffres, Jonathan D Campbell
Annals of Internal Medicine|April 4, 2018
A Call for Open-Source Cost-Effectiveness AnalysisR Brett McQueen, William V Padula, Jonathan D Campbell
JAMA Oncology|October 17, 2018
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell ImmunotherapyMelanie D Whittington, Daniel A Ollendorf, Jonathan D Campbell
The American Journal of Managed Care|July 24, 2025
Challenges with judging and interpreting a drug's launch priceMelanie D Whittington, Louis P Garrison, Jonathan D Campbell
Health Affairs Scholar|June 17, 2026
Association of 340B entity eligibility with changes in hospital financial performanceNeal Masia, Jonathan D Campbell, Yevgeniy Feyman, et al.
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
JAMA Pediatrics|March 20, 2018
Considerations for Cost-effectiveness Analysis of Curative Pediatric TherapiesMelanie D Whittington, R Brett McQueen, Jonathan D Campbell
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 6, 2008
Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthmaJonathan D Campbell, David K Blough, Sean D Sullivan
Health Affairs Scholar|September 8, 2025
Inflation reduction act impact on pharmaceutical investment: insights from investor interviewsWilliam J Canestaro, Julie A Patterson, Jonathan D Campbell
Neurology. Clinical Practice|May 1, 2018
Achieving high value care for all and the perverse incentives of 340B price agreementsMelanie D Whittington, Jonathan D Campbell, R Brett McQueen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment ImplicationsMelanie D Whittington, R Brett McQueen, Jonathan D Campbell
Hospital Pharmacy|May 6, 2022
Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant InfectionsMonica L Bianchini, Meghan N Jeffres, Jonathan D Campbell
Annals of Internal Medicine|April 4, 2018
A Call for Open-Source Cost-Effectiveness AnalysisR Brett McQueen, William V Padula, Jonathan D Campbell
JAMA Oncology|October 17, 2018
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell ImmunotherapyMelanie D Whittington, Daniel A Ollendorf, Jonathan D Campbell
The American Journal of Managed Care|July 24, 2025
Challenges with judging and interpreting a drug's launch priceMelanie D Whittington, Louis P Garrison, Jonathan D Campbell
Health Affairs Scholar|June 17, 2026
Association of 340B entity eligibility with changes in hospital financial performanceNeal Masia, Jonathan D Campbell, Yevgeniy Feyman, et al.
Pageof 13